EQS-News
BRAIN Biotech AG takes next step to optimize group structure
- BRAIN Biotech AG merges AnalytiCon Discovery GmbH
- Merger aims to optimize and simplify group structure
- No changes in operational business or employee status
EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous BRAIN Biotech AG takes next step to optimize group structure |
BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure.
Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG, with the approval of the Supervisory Board, has resolved to merge AnalytiCon Discovery GmbH with BRAIN Biotech AG. AnalytiCon Discovery GmbH, based in Potsdam, Germany, is already a fully owned subsidiary of the BRAIN Biotech Group.
This legal reorganization will further optimize and simplify the structure of the BRAIN Biotech Group. The operational business of both units remains unaffected and will continue unchanged at the respective locations.
Michael Schneiders, CFO of BRAIN Biotech AG, comments on the merger: "Last year we have merged our product business under the umbrella of Biocatalysts. We are now taking the next logical step by legally combining our scientific services in the BioScience business segment under the umbrella of the BRAIN Biotech AG. This will not result in any noticeable changes for our employees at both locations or for our business partners."
Further documents on the resolved merger of BRAIN Biotech AG with AnalytiCon Discovery GmbH can be viewed on the company's website at https://www.brain-biotech.com/merger-information.
+++
About BRAIN Biotech
BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.